Description
Carvenol (Carvedilol) 6.25 mg
Carvenol 6.25 mg is a carvedilol tablet. Carvedilol is a prescription alpha- and beta-adrenergic blocking medicine used in cardiovascular care. The verified active ingredient for this product is carvedilol, and the 6.25 mg strength identifies the tablet formulation.
Active Ingredient and Medicine Class
Active ingredient: carvedilol.
Medicine class: non-selective beta-blocker with additional alpha-1 blocking activity. This dual action helps lower blood pressure and reduce the heart’s workload. Carvedilol is considered a vasodilating beta-blocker.
Established Medical Uses
Regulatory prescribing information identifies carvedilol tablets for the treatment of mild to severe chronic heart failure, left ventricular dysfunction following myocardial infarction in clinically stable patients, and hypertension.
In heart failure, carvedilol is used as part of established cardiovascular therapy to help improve long-term outcomes in appropriate patients. In hypertension, it is used to lower elevated blood pressure. In certain patients after myocardial infarction, it is used to reduce cardiovascular risk when left ventricular dysfunction is present.
How It Works
Carvedilol blocks beta receptors in the heart and circulation and also blocks alpha-1 receptors in blood vessels. Beta blockade slows the heart’s response to stress hormones, while alpha-1 blockade helps relax blood vessels. Together, these effects can reduce blood pressure, decrease cardiac workload, and improve the efficiency of the heart in selected cardiovascular conditions.
Scientific reviews also describe additional pharmacological properties, including vasodilatory effects and antioxidant activity, although the main clinically established actions are adrenergic receptor blockade and blood-pressure reduction.
Important Safety Information
Carvedilol should not be used in patients with bronchial asthma or related bronchospastic conditions, severe bradycardia, second- or third-degree atrioventricular block, sick sinus syndrome, cardiogenic shock, decompensated heart failure requiring intravenous inotropic therapy, severe hepatic impairment, or a serious hypersensitivity reaction to carvedilol or related products.
Important precautions include the risk of bradycardia, hypotension, fluid retention or worsening heart failure, and bronchospasm in susceptible patients. Abrupt discontinuation can worsen coronary artery disease or angina symptoms, so therapy changes require clinical supervision.
Clinically significant interactions may occur with other medicines that lower heart rate or blood pressure, including certain calcium channel blockers, digoxin, amiodarone, clonidine, reserpine, and monoamine oxidase inhibitors. CYP2D6 inhibitors may increase carvedilol exposure, while rifampin may reduce it. Carvedilol may also affect glucose control and can mask some warning signs of low blood sugar.
Possible Side Effects
Common adverse effects reported in prescribing information include dizziness, fatigue, hypotension, diarrhea, bradycardia, asthenia, weight increase, and, in some settings, hyperglycemia. Dizziness is a frequent complaint in treatment for hypertension.
More serious reactions can include marked slowing of the pulse, fainting, worsening heart failure, severe low blood pressure, bronchospasm, allergic reactions, and liver-related problems in susceptible individuals.
Scientific Evidence
Clinical reviews and trials support carvedilol as an effective therapy in chronic heart failure, where it has been associated with improvements in left ventricular function and reductions in morbidity in studied populations. Reviews of hypertension research also describe carvedilol as a vasodilating beta-blocker that lowers blood pressure by decreasing vascular resistance and may have a more favorable metabolic profile than some older beta-blockers.
These findings support its established cardiovascular role, but individual benefit depends on the clinical context, underlying condition, and tolerance of therapy.
Medical Information Notice
This summary is based on official prescribing information and selected peer-reviewed literature available at the time of review. It is for educational purposes only and does not replace the official patient leaflet, product label, or assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration / DailyMed Carvedilol tablet, film coated. Official prescribing information. View official label
- Gillian M Keating et al. Carvedilol: a review of its use in chronic heart failure. Drugs, 2003. View scientific article
- Gastone Leonetti et al. Use of carvedilol in hypertension: an update. Vascular Health and Risk Management, 2012. View scientific article